I think finish the ascending dose study, file the NDA at that point, gain approval for the first PMO ever, say yes to the DoD's request for a stockpile order as long as it does not in any way impact negatively the DMD program. If it does, tell them we can't do it. And then , allow the DoD to disseminate the drug as they see fit. Hopefully, there will be some protocols developed so that proper triage can be done with regards to who gets the drug and when.
the funniest thing of all is Star, that you and your aliases have so polluted this board, that at this very moment, when I look at the screen, there is ONLY this one post that Simp started this morning that shows up. The rest is one form of #$%$ or another. Freaking hilarious. What a sad little wasted life you lead. BAck in the cave you go pin head.
please state which instance that his timeline for bringing Eteplirsen forward AFTER the FDA got off of their a$$es and gave guidance has not been met, or exceeded. Thank you in advance for sharing these instances for the world to see in support of your CEO stance.
Hint: there AREN'T any examples because CG has kept the company focused on the prize and they are exactly on the schedule that he said they would be on. You, sadly, remain pure, and complete I D I O T :-)
I agree that ebola will never be a big money maker. That said, if a government stock pile order were to come along, which is possible given the current state of affairs in the world, that would certainly be a profitable transacton for SRPT. I do agree though, that the main benefit to the company would be validation of their IP for a completely different target. If it gets thrown into action, I hope their ebola drug is both safe and effective. It certainly seems to be safe with the data generated so far. As jrrt1 has suggested, it would not take that much man power to complete the ascending dose part of the trial, and then submit an NDA. It's fun to talk about, but the elephant in the room is, and will be, DMD/Eteplirsen. CG knows this and has done a good job of keeping things on track despite enduring some tumultuous times management wise.
I could not agree more Simp. I thought that was the one glaring flaw in that scientists article. He was still stuck in the antiquated belief that "leaky cell" was the mechanixm of entry. Myogenesis is actually far more favorable with regards to PMO's being effective long term IMHO.
Perhaps he was so focused on using all of his big words, that he forgot to notice the difference between "ebola half-life" and drug half life? Nah, yet another example of Pasteur's deliberate attempts to mislead. What a miserable life.
"he wasted"? Yo knucklehead, the FDA were, and continue to be, the ones with the power to move things forward. And they were busy obtaining a greater than 8 th grade understanding of DMD, FDASIA, dystropphin assessment, and more. It wasn't CG who forced them to #$%$ away all that time. CG didn't encourage them to draw conclusions from data they didn't even posses!
I'm sure CG would have gladly started a full P3 after the 48 week data came in, had the FDA simply said, we like the P2, but you should start your P3 right away cuz we're gonna want to see it. BUT.................they didn't......and see if you can grasp this..........CG did't make them do it. Why I read any of your flotsam escapes me. It's always a mistake.
Funny stuff. Save your energy Jim, they aren't budging. For that to happen, it will have to be jammed right down their throat with force. They didn't cover 52-12's, and they aren't about to cover here either. Good 4th biopsy data might change their minds though, cuz if/when that happens, we're good to go, platform soon to follow AA.
All I remember is them working with a university in Oregon on developing an antibiotic that did not allow resistance to develop, and the work seemed promising.
Pretty sure the university released some form of PR along that line a while back.
unlikely. It will not be valued in the BILLIONS with zero cash flow. Sure, the license will push share price up, but the "B's" take actual cash flow.